We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Surface Plasmon Resonance Technique Provides Rapid Profiling of Autoantibodies in Rheumatoid Arthritis

By Biotechdaily staff writers
Posted on 26 Nov 2007
Using a new imaging technique, a fast and accurate profile of autoantibodies present in the blood serum of rheumatic patients can be made. More...
This profile can give valuable information about the progress of the disease. A unique feature of this so-called surface plasmon resonance (SPR) technique is that it directly tests on blood serum, without complicated preprocessing.

Using SPR, a special chip will enable many parallel tests. Scientists from the University of Twente (Enschede, The Netherlands) and the Radboud University Nijmegen (The Netherlands) will publish data about the new imaging technique in an upcoming issue of the Journal of the American Chemical Society (JACS).

The investigators have run tests on the serum of 50 rheumatoid arthritis (RA) patients as well as a control group of 29 individuals. Direct testing on blood serum is unique: in other techniques, fluorescent labels and preprocessing is necessary to visualize the relevant proteins. The diluted serum is led over a special gold-coated microchip containing a large number of spots with a specific peptide coating. Whenever these peptides interact with autoantibodies present in the serum, this process can be monitored by SPR imaging. Using laser light, all gold spots are scanned: the reflection of light of the spots changes whenever there is a molecular interaction on the spot. At a certain angle of light, there is no reflection at all: this is the so-called SPR dip undergoing a shift caused by the interaction. The technique goes beyond establishing that autoantibodies are present: the interaction between the protein and the antibody can be monitored in real time and without any labels.

Autoantibodies are manufactured by the immune system as a reaction on the so-called citrullinated proteins playing a role in rheumatoid arthritis. On a single chip, several types of peptides can be placed, for rapid parallel screening. The next step will be, according to the scientists, to investigate in what way the patient profiles help to monitor the progress of the disease, which could lead to more customized treatments in the future. The applications are not limited to monitoring RA or other autoimmune diseases: SPR imaging can be used for monitoring a wide range of biomolecular interactions.


Related Links:
University of Twente
Radboud University Nijmegen

Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Pipette Controller
Sapphire MaxiPette
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.